GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2007

Lilly Gains Access to Ambrx’ Protein Optimization Technology

  • Ambrx signed a research collaboration with Eli Lilly to discover and develop novel treatments in several therapeutic areas including metabolic diseases, central nervous system disorders, and other diseases.

    The companies will apply Ambrx’ protein optimization technology, ReCODE™, with Lilly's expertise in biologics discovery, development, and commercialization to pursue drug candidates including therapeutic antibodies and improved variants of native proteins.

    Under the terms of the agreement, Ambrx will receive an initial upfront payment and ongoing research support payments. Additionally, Ambrx may receive potential research and development milestones and additional royalties if assets resulting from the collaboration are successfully commercialized.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?